Hypnion's HY10275 meets Ph II endpoints

15 January 2007

US drugmaker Hypnion says that its drug candidate HY10275 met the primary and secondary endpoints of an initial Phase II trial evaluating the dual-acting H1 / 5HT2a compound in transient insomnia.

In the randomized, double-blind, placebo-controlled, 52-patient study, HY10275 demonstrated statistically-significant improvements in Wake After Sleep Onset, an objective measure of sleep maintenance. WASO decreased in a dose-dependent manner by 62 minutes for those on 3mg of the drug (p<0.001) and 35 minutes with 1mg (p<0.002), compared to placebo. Patients with moderate-to-severe transient insomnia responded as well as or better than those with mild-to-moderate transient insomnia, the firm noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.